Abstract:Background: CD8+ T cells are a highly diverse population of cells with distinct phenotypic functions that can influence immunotherapy outcomes. Further insights on the roles of CD8+ specificities and TCR avidity of naturally arising tumor-specific T cells, where both high and low avidity T cells recognizing the same peptide-major histocompatibility complex (pMHC) coexist in the same tumor, are crucial for understanding T cell exhaustion and resistance to PD-1 immunotherapy. Methods: CT26 models were treated with anti-PD-1 on days 3, 6 and 9 following subcutaneous tumor implantation generating variable responses during early tumor development. Tetramer staining was performed to determine the frequency and avidity of CD8+ T cells targeting the tumor-specific epitope GSW11 and confirmed with tetramer competition assays. Functional characterization of high and low avidity GSW11-specific CD8+ T cells was conducted using flow cytometry and bulk RNA-seq. In vitro cytotoxicity assays and in vivo adoptive transfer experiments were performed to determine the cytotoxicity of high and low avidity populations. Results: Treatment success with anti-PD-1 was associated with the preferential expansion of low avidity (Tetlo) GSW11-specific CD8+ T cells with Vβ TCR expressing clonotypes. High avidity T cells (Tethi), if present, were only found in progressing PD-1 refractory tumors. Tetlo demonstrated precursor exhausted or progenitor T cell phenotypes marked by higher expression of Tcf-1 and T-bet, and lower expression of the exhaustion markers CD39, PD-1 and Eomes compared with Tethi, whereas Tethi cells were terminally exhausted. Transcriptomics analyses showed pathways related to TCR signaling, cytotoxicity and oxidative phosphorylation were significantly enriched in Tetlo found in both regressing and progressing tumors compared with Tethi, whereas genes related to DNA damage, apoptosis and autophagy were downregulated. In vitro studies showed that Tetlo exhibits higher cytotoxicity than Tethi. Adoptive transfer of Tetlo showed more effective tumor control than Tethi, and curative responses were achieved when Tetlo was combined with two doses of anti-PD-1. Conclusions: Targeting subdominant T cell responses with lower avidity against pMHC affinity neoepitopes showed potential for improving PD-1 immunotherapy. Future interventions may consider expanding low avidity populations via vaccination or adoptive transfer.

Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy

PD-1+ stemlike CD8 T cells are resident in lymphoid tissues during persistent LCMV infection

Characteristics and anatomic location of PD-1+TCF1+ stem-like CD8 T cells in chronic viral infection and cancer

Epigenetic signature of PD-1+ TCF1+ CD8 T cells that act as resource cells during chronic viral infection and respond to PD-1 blockade

PD-1 blockade increases the self-renewal of stem-like CD8 T cells to compensate for their accelerated differentiation into effectors

TGF-β regulates the stem-like state of PD-1+ TCF-1+ virus-specific CD8 T cells during chronic infection

PD-1 Expression on Memory CD8 and CD4 T-cell Subsets in Healthy Humans (43.43)

Reinvigorated exhausted T cells exhibit distinct features within 24 hours after PD-1 therapy

Dynamic CD4+ T cell heterogeneity defines subset-specific suppression and PD-L1-blockade-driven functional restoration in chronic infection

CD8+ T Cells Specific for Both Persistent and Non-Persistent Viruses Display Distinct Differentiation Phenotypes but Have Similar Level of PD-1 Expression in Healthy Chinese Individuals

Restoring function in exhausted CD8 T cells during chronic viral infection

mTOR signals regulate T cell exhaustion and T cell responses during PD-1 targeted immunotherapy in chronic viral infection.

Genetic absence of PD-1 promotes accumulation of terminally differentiated exhausted CD8+ T cells

PD-1 controls differentiation, survival, and TCR affinity evolution of stem-like CD8+ T cells

PD-1 combination therapy with IL-2 modifies CD8 + T cell exhaustion program

PD-1 immune checkpoint blockade can synergize with PSGL-1 inhibition to reinvigorate exhausted T cells

Chronic viral infection alters PD-1 locus subnuclear localization in cytotoxic CD8+ T cells

Proliferation of Pd-1+Cd8 T Cells in Peripheral Blood after Pd-1-Targeted Therapy in Lung Cancer Patients

CD8+CD57+ T Cells Exhibit Distinct Features in Human Non-Small Cell Lung Cancer

Reactivation of low avidity tumor-specific CD8+ T cells associates with immunotherapeutic efficacy of anti-PD-1

Phenotypic and Functional Analysis of LCMV Gp 33-41-specific CD 8 T Cells Elicited by Multiple Peptide Immunization in Mice Revealed the Up-regulation of PD-1 Expression on Antigen-Specific CD 8 T Cells